zinc finger protein 646 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored ZNF646P1 profile across patient tissues and cancer cell-line models. ZNF646P1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZNF646P1 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, ZNF646P1 RNA expression shows 5,739 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, THCA, and STAD as cancer lineages where ZNF646P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF646P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF646P1 survival associations across molecular data types. ZNF646P1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF646P1 RNA expression–survival associations across cancer types. High ZNF646P1 expression shows unfavorable associations in UCS, ACC, LUAD, THYM, BLCA and THCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for ZNF646P1 RNA expression.
This table summarizes ZNF646P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF646P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF646P1 shows lower tumor expression in THCA. The THCA box plot shows higher ZNF646P1 RNA expression in normal versus tumor tissue (log2 FC = −0.019, t-test p = .002).
This table shows molecular features associated with ZNF646P1 in patient tissues and cancer cell lines. In patient samples, ZNF646P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
